🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
BioVie Inc. (BIVI)
NASDAQ: BIVI · Real-Time Price · USD
0.8000
-0.1098 (-12.07%)
At close: Nov 20, 2026, 4:00 PM EST
0.9393
+0.1393 (17.41%)
After-hours: Nov 20, 2026, 7:35 PM EST

Company Description

BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States.

The company develops BIV201, that is in phase 3 for the treatment of life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism.

It also develops Bezisterim, an investigational, novel, orally administered small molecule that is In Phase 3 clinical trial for the treatment of patients with mild to moderate Alzheimer’s disease; and in Phase 2b clinical trial to treat Parkinson’s disease, as well as for the long COVID program.

The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016.

BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.

BioVie Inc.
BioVie logo
CountryUnited States
Founded2013
IndustryBiotechnology
SectorHealthcare
Employees13
CEOCuong Viet Do

Contact Details

Address:
680 W. Nye Lane, Suite 2014
Carson City, Nevada 89703
United States
Phone775 888 3162
Websitebioviepharma.com

Stock Details

Ticker SymbolBIVI
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJuly - June
Reporting CurrencyUSD
CIK Code1580149
CUSIP Number09074F504
ISIN NumberUS09074F5044
Employer ID46-2510769
SIC Code2834

Key Executives

NamePosition
Cuong Viet Do M.B.A.President, Chief Executive Officer and Director
Joanne Wendy Kim CPAChief Financial Officer, Treasurer and Corporate Secretary
Dr. Joseph M. Palumbo M.D.Executive Vice President of Research & Development and Chief Medical Officer
Clarence N. AhlemSenior Vice President of Operations
Dr. Penelope Markham Ph.D.Senior Vice President of Liver Disease and Long COVID Programs
Denise SmithSenior Vice President of Manufacturing and Development
Dr. Christopher L. Reading Ph.D.Senior Vice President of Alzheimer's Disease Program
David MorseSenior Vice President and Chief Regulatory Officer

Latest SEC Filings

DateTypeTitle
Nov 19, 2026DNotice of Exempt Offering of Securities
Nov 18, 2026S-8Securities to be offered to employees in employee benefit plans
Nov 10, 20268-KCurrent Report
Nov 6, 202610-QQuarterly Report
Nov 6, 20268-KCurrent Report
Nov 6, 2026SCHEDULE 13G/AFiling
Nov 5, 2026424B5Filing
Nov 5, 2026424B5Filing
Nov 4, 2026424B5Filing
Sep 28, 2026DEF 14AOther definitive proxy statements
Investor Relations Documents
Annual and quarterly reports, earnings releases, and presentation slides